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Abstract 
We designed the present study to provide evidence of the 
immunomodulatory effects of pentoxifylline (PTX) in experimental 
autoimmune myocarditis (EAM) in rats. PTX is xantine-derived agent 
known to inhibit the production of TNF-α and his beneficial effects have 
been reported in patients with dilated cardiomyopathy. In this study we 
examined the efficacy of PTX in the treatment of experimental 
autoimmune myocarditis as a paradigm of the autoimmune mechanisms 
involved in pathogenesis of dilated cardiomiopathy. Male DA rats 
immunized with porcine cardiac myosin were treated  i.m. with PTX 
(200 mg/kg/day) over 7 days, begenning either on the day of 
immunization (early treatment group), or on day 14. postimmunization 
(late treatment group). Disease course and severity were evaluated by 
macroscopic score of the heart, heart weight/body weight ratio (Hw/Bw), 
histological and immunohistochemical analysis of cardiac tisssue. We 
found in our study that PTX exhibited both preventive and therapeutical 
effects in EAM. 
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Introduction 
Inflammatory heart disease caused by Coxsackieviruses belongs to 
the most frequent cardiac complications of this infection in adults. 
Although there is no doubt that the virus damages cardiomyocytes 
directly, there is compelling evidence from clinical studies, and 
particularly, from a variety of murine models, suggesting that the tissue 
injury is primarily mediated by autoimmune mechanisms (1, 2, 5). 
Immunization with cardiac myosin induces severe myocarditis in 
genetically predisposed animals. Cardiac myosin-induced myocarditis 
offers a virus-free system with a defined autoantigen and possibility to 
study autoimmune mechanisms in postviral heart disease. The disease 
closely parallels with human one seen after infection with Coxsackievirus 
B3 and is characterized by enlargement of the heart, marked cellular 
infiltration consisting of mononuclear cells, neutrophils, fibroblasts and 
multinucleated giant cells. Extensive myocardial necrosis is also present 
(4,12,13).  
There is accumulating evidence supporting the view that 
proinflammatory cytokines play a crucial role in the pathogenesis of viral 
myocarditis and dilated cardiomyopathy. Okura and his collaborators 
have demonstrated that cytokines relating to inflammation are involved 
in the induction and resolution of EAM.  
Th1 type cytokines (IL-2 and IFN-γ) and proinflammatory 
cytokines (IL-1 and TNF-α) have been detected only in the inflammatory 
phase, while the production of a Th2 cytokines has been found in the 
recovery phase (4). Smith and his collaborators have demonstrated that 
anti-TNF-α antibody reduced severity of EAM and suggested that TNF-
α is an important early mediator in the pathogenesis of inflammation 
(19). 
 In the present study the immunomodulatory potential of 
pentoxifylline was investigated in EAM. Pentoxifylline (3,7-dimethyl-1-
(5-oxohexyl) xantine) a phosphodiesterase inhibitor, is a widely used 
vasoactive drug with proven clinical efficacy in microcirculatory 
disorders (21, 22, 23). Recently the potential use of PTX as an 
antiinflammatory drug has gained increasing interest because in vitro and 
in vivo studies have shown that PTX suppresses or reduces the 
production of TNF-α (24).  Inhibitory effect of PTX on TNF-α 
production is exerted at the transcriptional level, by elevating the 
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intracellular level of second messenger cAMP (18, 20). It has been 
shown that PTX in vitro could suppress T-cell proliferation and 
production of TNF-α and IFN-γ (20 ).   
It has been reported that PTX can inhibit the onset or severity of 
organ-specific autoimmune diseases such as experimental autoimmune 
encephalomyelitis (18).  
In recent years, the potential use of PTX as an antiinflammatory 
drug has gained increasing interest because in vitro and in vivo studies 
have shown that PTX suppresses or reduces the production of TNF-α, 
and has beneficial effects in disorders such as graft-versus-host disease, 
cerebral malaria and acute hepatitis, in which TNF-α has an important 
role (11).  
Materials and methods 
Immunization and treatment 
Male 8-week-old DA rats were bred and maintained at the Animal 
house of Military Medical Academy, Belgrade. Rats were immunized 
subcutaneously with 5 mg/kg of porcine cardiac myosine (Sigma, St 
Louis, MO, USA) emulsified with an equal volume of complete Freund΄s 
adjuvant supplemented with (0.1mg/0.1ml) Mycobacterium tuberculosis 
H37RA (Difco).  Pentoxifylline (Pharma-Synthesis Department, Hoechst, 
Wiesbaden, Germany) was administered i.m. at a dose of 200 mg/kg 
either during the first 6 days (early treatment group), or starting from 14 
and ending at day 20 after disease induction (late treatment). Control 
animals received equal volume of saline during the same periods. 
Efficacy of PTX treatment was determined on day 21 of EAM 
development. 
Macroscopic findings and  histological analysis 
All rats were sacrificed under ether anesthesia and disease severity 
was evaluated by macroscopic findings of the hearts, heart weight / body 
weight (Hwt/Bwt) ratio, as well as by histological and immunohisto-
chemical analysis. Macroscopic findings were scored as follows:                     
0-normal finding; 1-presence of focal discolored area on the cardiac 
surface; 2-presence of diffuse discolored areas not exceeding a total of 
one-third of the cardiac surface; 3-diffuse discolored areas totaling more 
than one-third of the cardiac surface. For microscopic grading, transverse 
sections through the middle of the heart were fixed in 10% buffered 
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formalin and embedded in paraffin according to the conventional 
procedure. Paraffin-embedded tissues were cut (5 µm in thickness) and 
stained with hematoxylin-eosin for histological examination. The 
severity of myocarditis was classified into 4 grades: 0, no inflammation; 
1, histological cross section infiltrated up to 5%; 2, 5-10% 
infiltrates/section; 3, 10-20% infiltrates/section; 4, more than 20% 
infiltrates/section. The presence of multinucleated giant cells did not 
influence microscopic score. 
Immunohistochemical analysis 
For immunohistochemical staining heart samples were embedded 
in OCT (optimal cutting temperature) compound (Miles, Elkhart, IN) and 
rapidly frozen. Cryostat sections were cut sequentially at 7 µm in 
thickness, mounted on glass slides and prepared for immunoperoxidase 
and immunoalkaline phosphatase staining. Sections were fixed in cold 
acetone for 10 min. and extensively washed in 0.1 M Tris buffer solution 
(pH 7.6). Murine monoclonal antibodies specific for different rat 
molecules (Table I) were added at appropriate concentrations in 
sufficient amount to cover the sections. After incubation at 4ºC over 
night and further buffer washes, the sections were incubated with 
peroxidase-conjugated rabbit anti-mouse immunoglobulins (P0161, 
Dako, Denmark) for 60 min. Peroxidase reaction was visualized with 
0.05% diamino benzidine (DAB) in 0.01% H2O2 for 6-8 min. The color 
development was stopped by washing slides in running water. Some 
cryostat sections were stained by alkaline phosphatase method. After 
incubation with appropriate mouse anti-rat monoclonal antibodies, 
sections were incubated with rabbit anti-mouse immunoglobulins 
(Z0109, Dako, Denmark)  for 60 min. at room temperature, washed and 
additionally incubated with APAAP (D651, Dako, Denmark) for 40 min. 
The alkaline phosphatase reaction was visualized by naphtol substrate 
containing naphtol phosphate, dimethyl formamide, 0.1M Tris pH 8.2, 
1M levamisole and fast red. All samples were lightly counterstained with 





Table I    Murine monoclonal antibodies specific for rat antigens 
Tabela I  Monoklonska antitela specifična za različite antigene  
                ćelija pacova 
 










































*  Monoclonal antibodies R-MC42 and R-MC46 were produced in  
    the Institute of Medical Research, MMA, Belgrade 
 
Statistical analysis 
The heart macroscopic and microscopic scores were expressed as 
mean values. Body weights (Bwt), heart weights (Hwt) and Hwt/Bwt 
ratio were expressed as mean ± 1SD. Student΄s t-test was used for 
comparison data between groups. Differences were considered 
significant at p< 0.05. 
Results and discussion 
Effects of PTX on experimental autoimmune myocarditis were 
evaluated by two treatment protocols: the first conducted within the first 
6 days after induction EAM (early treatment group); and the second, 
started 14 days and ended 20 days after induction of EAM (late treatment 
group). Both groups received i.m. 200 mg/kg/day of PTX. Animals were 
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killed on day 21, their hearts were analyzed macroscopically and 
microscopically and compared with control group of rats (Table II). 
 
 Table II   Effects of Pentoxifylline on incidence of experimental  
                           autoimmune myocardits, body weight (Bwt), heart  
                           weight (Hwt), index Hwt/Bwt, and macroscopic and  
                           microscopic scor of disease in rats treated with PTX  
                           (200mg/kg) over 6 days  from the day of immunization  
                            (A); in rats subjected to the same treatment from day  
                           14th postimmunization (B), control  immunized (C) and  
                            in unimmunized rats (D) 
Tabela II Efekat pentoksifilina na incidencu eksperimentalnog  


























































C 14/14 (100) 
 
186.0 ± 4.0 
 

























*       Statistical significance p< 0.05 between treated groups vs. C control group 
 **      Statistical significance p< 0.01 between treated groups vs. C control group 
 
Macroscopic and microscopic findings. While diseased rats 
progressively decreased body weights over 21-day-long 
postimmunization period, the rats treated with PTX  did not change body 
weight in comparison with the starting values. The heart weights in rats 
treated with PTX were significantly lower (p< 0.05) than that of 
untreated animals, while no difference was detected in the value of this 
parameter between PTX-treated groups. Hwt/Bwt ratios were also 
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significantly lower (p < 0.01) in both groups of PTX treated animals 
compared with the saline injected controls, and did not differ from the 
values of the healthy control. Saline injected animals, immunized with 
cardiac myosin, exhibited discolored areas over the cardiac surface 
(mean macroscopic score 1.9), had numerous inflammatory infiltrates in 
the heart tissue and showed extensive myocardial necrosis (Fig.1). In the 
early PTX-treated group, only one heart that appeared macroscopically 
normal, microscopically showed mild inflammation (mean microscopic 
score 0.2). In the group treated later with PTX, mild to moderate 
inflammation was detected in two hearts, but the mean microscopic score 
was 0.4, still markedly lower than that of untreated animals. Taken 
together, 28% (2/7) animals developed mild myocarditis when they were 
treated from day 14 to day 20 after immunization.     
Immunohistochemical analysis of heart sections from animals 
trated early with PTX demonstrated no differences in comparison with 
the normal heart tissue. The number of CD4+ cells in the animals treated 
early with PTX was markedly lower than in saline injected controls 
(Fig.1).  In one case, small subepicardial clusters of mononuclear cells 
not exceeding 10-15 cells/cluster (microscopic score 0.2) were observed 
(Table 2). In late treatment group two hearts had rare, small-sized 
infiltrates, showed the increased expression of adhesion molecules on the 
interstitial and vascular endothelial cells. In these rats OX-6+, R73+ and 
CD4+ cells were slightly more frequent (not statistically significant) than 
in healthy control animals.  
According to the histological and immunohistochemical findings, 
the early PTX treatment prevented the disease development, while the 
late PTX treatment effectively suppressed myocarditis. 
It has been  reported that cytokines relating to inflammation are 
involved in the induction and resolution of EAM (4). Th1 type cytokines 
produced mainly by infiltrating lymphocytes, and proinflammatory 
cytokines produced by the infiltrating macrophages, were detected only 
in the inflammatory phase (day 19-25) of EAM, while in the recovery 
phase the expression of a Th2 cytokine, IL-10, and TGF-β was observed 
(5, 8, 11). We demonstrated histologically and immunohistochemically 
the inhibitory effect of PTX on myocardial inflammation, early treatment 
was demonstrated to prevent the disease development, while late 
treatment significantly reduced the severity of EAM. It is reasonable to 
believe that the drug specifically targets production of proinflammatory 
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cytokines, although there may be also some other explanations. For 
example PTX has been found to inhibit apoptosis in different human cell 
types (20). Further investigation is necessary to test if PTX prevent the 
apoptotic cell death of cardiomyocytes,  as well as its putative effect on 
the chronic phase of EAM. 
In conclusion, in our study we found that PTX exhibited both 




a. Inflammatory infiltrate in EAM at day 21, untreated animal                            
(HE staining, magnification x 125)  
        Inflamatorni infiltrat u EAM 21-og dana, netretirane životinje 
b. PTX-treated animal in EAM at day 21, (HE staining, magnification x 125)                                                        
PTX-tretirana životinja, EAM, 21 dan 
c. CD4+ cells in untreated animal, EAM at day 21, (magnification x 500)  
       CD4+ ćelije u netretirane životinje, EAM, 21 dan 
d. CD4+ cells in PTX treated animal (0-6 day), (magnification x 500)  
       CD4+ ćelije u životinje tretirane PTX (0-6 dan) 
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Kratak sadržaj 
U radu je ispitivan uticaj pentoksifilina (PTX) na razvoj i tok 
eksperimentalnog autoimunog miokarditisa pacova. Pentoksifilin je 
derivat ksantina sa inhibitornim efektom na produkciju TNF-α, a klinički 
je potvrđen i njegov pozitivan učinak u terapiji pacijenata sa 
dilatacionom kardiomiopatijom. U ispitivanju je testiran 
imunomodulatorni efekat PTX u tretmanu eksperimentalnog autoimunog 
miokarditisa koji predstavlja eksperimentalni model za proučavanje 
autoimunskih mehanizama uključenih u razvoj dilatacione 
kardiomiopatije. Pacovi DA soja imunizovani srčanim miozinom tretirani 
su pentoksifilinom u dozi od 200 mg/kg t.m., počev od 0.-6. dana (rani 
tretman), ili od 14.-20. dana (kasni tretman) u odnosu na termin 
imunizacije miozinom. Razvoj i intenzitet miokarditisa praćeni su 
analizom makroskopskih karakteristika srca, indeksa masa srca/telesna 
masa (Hwt/Bwt), histoloških i imunohistohemijskih analiza miokarda. 
Dobijeni rezultati su pokazali da PTX ispoljava profilaktičan i terapijski 
učinak u eksperimentalnom autoimunom miokarditisu. 
 
Ključne reči: srčani miozin, autoimunski miokarditis,  
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